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Angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), 
AT1-receptor antagonists or sartans, block the activation of angiotensin II AT1 receptors. 
ARBs directly cause vasodilatation, reduce secretion of vasopressin, and reduce the 
production and secretion of aldosterone. Angiotensin-converting enzyme (ACE) inhibitors 
block the conversion of angiotensin I to angiotensin II and inhibit the breakdown of 
bradykinin, resulting in physiological benefits that confer cardioprotective and 
renoprotective properties. 
 
Both ARBs and ACE inhibitors are classes of drugs frequently used for the treatment of 
hypertension in daily clinical practice. They have protective effects on the heart and kidney 
and also lower blood pressure as well as improve insulin sensitivity. 
There are a number of studies on the effects of either ARBs or ACE inhibitors on metabolic 
parameters, cytokines or cardiovascular biomarkers1. However,  there are very few, if any, 
studies directly comparing the effects of ARBs with those of ACE inhibitors on metabolic 
parameters. 
 
In the current issue of Hypertension Research, Derosa and coworkers describe a study in 
which they recruited 228 Caucasian hypertensive subjects (115 males and 113 females) in a 
double-blind clinical trial. The authors found that 14 months of treatment with losartan 
improved a wide range of metabolic parameters (M value and levels of adiponectin, 
retinol-binding protein-4 (RBP-4), resistin, visfatin, vaspin) and vascular remodeling 
biomarkers (metalloproteinase-2 (MMP-2), MMP-9), whereas ramipril had no effect on any 
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of these parameters2 [figure 1], although those two drugs reduced blood pressure to 
comparable levels.  
 
Several investigators have reported that losartan treatment increased total serum 
adiponectin and high-molecular-weight adiponectin in IFG/IGT3 or hypertensive subjects4. 
Telmisartan was also demonstrated to increase serum adiponectin levels1. In contrast, 
another study showed that 8 weeks of telmisartan treatment had a neutral effect on insulin 
resistance, as assessed by HOMA-IR in hypertensive subjects with metabolic syndrome. 
 
So what is the potential mechanism by which these ARBs increased adiponectin levels? 
Is this directly related to AT1 receptor block? The most conceivable explanation for this is 
peroxisome proliferator-activated receptor (PPAR) activation by these ARBs. A subset of 
ARBs, including losartan, induce the activity of PPAR by partial agonism5. Of note, this 
activation was independent of AT1R expression and therefore not related to AT1R-blocking 
properties5. PPAR functions as a transcriptional regulator in adipose tissue, where it 
regulates multiple genes involved in lipid and glucose metabolism. In the case of 
telmisartan, our groups and others6 have shown that telmisartan treatment produced 
significant reductions in visceral fat areas but not subcutaneous areas evaluated by 
computed tomography in Japanese subjects with metabolic syndrome. Since plasma 
adiponectin level is inversely associated with visceral fat accumulation, we presumed that 
adiponectin increased after telmisartan treatment mainly through visceral fat mass reduction. 
In rats, visceral fat accumulation is suppressed by telmisartan treatment7. Telmisartan also 
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modulates adipocyte size and fat accumulation, resulting in protection against diet-induced 
visceral obesity. It is also likely that the increased expression of mitochondrial energy 
expenditure genes in skeletal muscle is the mechanism by which telmisartan decreases 
visceral fat accumulation, as previously shown in rat models. For the association between 
ramipril treatment and plasma adiponectin, on the other hand, previous findings are 
conflicting. One study performed in a randomized, double-blind, placebo-controlled 
cross-over manner showed 10 mg of ramipril, 16 mg of candesartan, or combination 
therapy increased plasma adiponectin levels when compared with baseline values8. Another 
study has shown that 9-week treatment with 10 mg of ramipril did not cause significant 
changes in adiponectin levels in patients with type 2 diabetes.  
 
Derosa et al. also investigated the effects of losartan versus ramipril treatment on several 
other metabolic parameters and vascular remodeling biomarkers2. To the best of our 
knowledge, there appears to be no previous report on the association of losartan and/or 
ramipril treatment with changes in RBP-4, visfatin or vaspin.  Also, there are very few 
reports, if any, on the effect of treatment with these compounds on serum resistin levels. A 
small crossover study by a Norwegian group composed of 23 hypertensive patients showed 
that there was no significant difference in blood levels of resistin (11.7 +/- 1.0 vs. 11.3 +/- 
0.7 ng/mL) between treatment with amlodipine 10 mg or losartan 100 mg + amlodipine 5 
mg, respectively. Since RBP-4, visfatin, vaspin and resistin are closely related to insulin 
resistance, the altered levels of these molecules along with adiponectin in the losartan group 
compared to the ramipril group in the current study suggest that losartan may have 
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considerable advantages over ramipril in the prevention of atherosclerotic disease or 
diabetes. The present finding that losartan but not ramipril caused a reduction in both 
matrix metalloproteinase (MMP)-2, and MMP-9 after 14 months (P<0.05) also suggests 
that losartan more effectively prevents the destabilization of plaques, as expected,  since 
MMPs are key enzymes involved in degrading extracellular matrix. However, a previous 
report9 showed that 10 mg once daily during 24 weeks of ramipril treatment reduced gene 
and protein expression of both MMP-2 and MMP-9. 
 
To what degree does losartan or ramipril prevent the incidence of cardiovascular disease or 
the onset of diabetes? The Losartan Intervention for Endpoint Reduction (LIFE), the Heart 
Outcomes Prevention Evaluation (HOPE) and the Diabetes REduction Assessment with 
ramipril and rosiglitazone Medication (DREAM) studies are large-scale randomized control 
trials (RCT) demonstrating the clinical outcome of using either losartan or ramipril. 
LIFE is a trial comparing the effect of losartan vs. atenolol, a selective β1 receptor 
antagonist, with regard to the incidence of cardiovascular mortality, fatal or nonfatal stroke, 
myocardial infarction or new-onset diabetes. The trial involved the recruitment of 9193 
hypertensive subjects with LVH. Main outcomes are a 25% further reduction in stroke and 
25% reduction of new-onset diabetes for losartan compared to atenolol, without a 
significant difference in MI incidence between groups. It should be noted, however, that 
LIFE did not necessarily demonstrate that long-term losartan therapy prevents the onset of 
diabetes because the study was performed with a β1 receptor antagonist rather than a 
placebo as control. 
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HOPE and DREAM are placebo-controlled RCT for investigating the long-term outcomes 
of ramipril use, with the former utilizing cardiovascular events as endpoints and with the 
latter utilizing new-onset diabetes or death as endpoints. The use of ramipril vs. placebo is 
associated with a 22% reduction in cardiovascular events without significant reductions in 
new-onset diabetes.  
 
So what about head-to-head RCT comparing ARBs versus ACE inhibitors? 
There are several RCT comparing ARBs versus ACE inhibitors in terms of mortality, 
morbidity or cardiovascular events as endpoints, but not the use of losartan vs. ramipril 
specifically.  In the ONgoing Telmisartan Alone and in Combination with Ramipril Global 
Endpoint Trial (ONTARGET), 25,620 subjects from 730 centers in 40 countries were 
high-risk patients with coronary, peripheral, or cerebrovascular disease or diabetes with 
end-organ damage. Patients were randomized to groups treated with 80 mg of telmisartan, 
10 mg of ramipril or both drugs and followed for 3.5 to 5.5 years. The authors concluded 
that telmisartan was an equally effective alternative to ramipril and that there is no 
additional advantage from the combination of full doses of telmisartan and ramipril 
compared with ramipril alone. The Optimal Trial in Myocardial Infarction with Angiotensin 
II Antagonist Losartan (OPTIMAAL) is a trial involving 5477 patients with confirmed 
acute myocardial infarction and heart failure recruited from 329 centers in seven European 
countries. Patients were randomly assigned and titrated to a target dose of losartan (50 mg 
once daily) or captopril (50 mg three times daily), with all-cause mortality as the primary 
endpoint. They concluded that ACE inhibitors should remain the first-choice treatment in 
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patients after complicated acute myocardial infarction. The VALsartan In Acute myocardial 
iNfarcTion (VALIANT) study compared the effect of valsartan (4909 patients), valsartan 
plus captopril (4885 patients), or captopril (4909 patients) on death from any cause in 
subjects with acute myocardial infarction who had already undergone conventional therapy. 
The authors concluded that valsartan is as effective as captopril in patients who are at high 
risk for cardiovascular events after myocardial infarction. Thus none of these three 
large-scale RCT concluded that ARBs are superior to ACE inhibitors with respect to 
long-term mortality, incidence of cardiovascular disease or new onset of diabetes. 
 
Are the observed favorable effects in the current study pharmacologic class effects or 
specific to the drugs studied? As mentioned earlier, certain ARBs may utilize mechanisms 
involved in PPAR activation that are independent of AT1 R-blocking properties. Indeed, 
Derosa and coworkers10 reported very recently a study comparing the effects of 1-year 
treatment with 8 mg/d candesartan or 10 mg/d olmesartan on various metabolic parameters 
related to insulin resistance. They report that candesartan but not olmesartan caused 
favorable changes in M-value, adiponectin, visfatin, RBP-4 and C-reactive protein, 
although comparable reductions were observed in blood pressure. These results suggest that 
the observed changes in metabolic parameters may be due to compound-specific effects 
rather than class effects. In the future, to compare head-to-head long-term outcomes, 
studies should consider specific ARBs or ACE inhibitors rather than broadly compare 
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Proposed effects of losartan therapy on adipocytokine and metalloproteinase production, as 
clarified in the study by Derosa and coworkers2. 
Losartan
Adiponectin ↑ 
Visfatin↑
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